Comprehensive Dermatologic Drug Therapy

Part I: Introduction 1 Basic Principles of Pharmacology 2 Principles for Maximizing the Safety of Dermatologic Drug Therapy 3 Polymorphisms: Why Individual Drug Responses Vary 4 Adherence to Drug Therapy 5 Medical Decision Making Part II: Important Drug Regulatory Issues 6 The FDA Drug Approval Process 7 Pharmacovigilance: Verifying that Drugs Remain Safe 8 Drugs Taken Off the Market: Important Lessons Learned Part III: Systemic Drugs for Infectious Diseases 9 Systemic Antibacterial Agents 10 Systemic Antifungal Agents 11 Systemic Antiviral Agents 12 Systemic Antiparasitic Agents Part IV: Systemic Immunomodulatory Drugs 13 Systemic Corticosteroids 14 Methotrexate 15 Azathioprine 16 Mycophenolates 17 Cyclosporine 18 Phosphodiesterase-4 and Janus Kinase Inhibitors 19 Cytotoxic Agents 20 Dapsone 21 Antimalarial Agents 22 Systemic Retinoids Part V: Drugs Used in Conjunction with UV or Visible Light 23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities 24 Extracorporeal Photochemotherapy (Photopheresis) 25 Photodynamic Therapy Part VI: Biologic Therapeutics 26 Tumor Necrosis Factor Inhibitors 27 Interleukin 12/23 Inhibitors 28 Interleukin 17 Inhibitors 29 Interleukin 23 Inhibitors 30 Rituximab 31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others Part VII: Miscellaneous Systemic Drugs 32 Antihistamines 33 Vasoactive and Antiplatelet Agents 34 Antiandrogens and Androgen Inhibitors 35 Psychotropic Agents 36 Intravenous Immunoglobulin Therapy 37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events 38 Hedgehog Pathway Inhibitors 39 Drugs for the Skinternist 40 Miscellaneous Systemic Drugs Part VIII: Topical Drugs for Infectious Diseases 41 Topical Antibacterial Agents 42 Topical Antifungal Agents 43 Topical and Intralesional Antiviral Agents 44 Topical Antiparasitic Agents Part IX: Topical Immunomodulatory Drugs 45 Topical Corticosteroids 46 Topical Retinoids 47 Topical and Intralesional Chemotherapeutic Agents 48 Topical Calcineurin Inhibitors 49 Topical Vitamin D3 Part X: Miscellaneous Topical Drugs 50 Sunscreens 51 Therapeutic Shampoos 52 a-Hydroxy Acids 53 Chemical Peels 54 Products for the Care of Chronic Wounds 55 Agents Used for Treatment of Hyperkeratosis 56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents 57 Miscellaneous Topical Agents Part XI: Injectable and Mucosal Routes of Drug Administration 58 Local Anesthetics 59 Injectable Dermal and Subcutaneous Fillers 60 Botulinum Toxin Injections 61 Oral Mucosal Therapeutics Part XII: Major Adverse Effects From Systemic Drugs 62 Hepatotoxicity of Dermatologic Drug Therapy 63 Hematologic Toxicity of Drug Therapy 64 Drug-induced Malignancy 65 Dermatologic Drugs During Pregnancy and Lactation 66 Drug Interactions 67 Cutaneous Drug Reactions With Systemic Features Part XIII: Special Pharmacology and Therapeutics Topics 68 Informed Consent and Risk Management 69 Compounding in Dermatology 70 Dermatologic Drug Therapy in Children Appendix I Core Questions for Understanding Systemic Dermatologic Drugs Appendix II The Most Potentially Serious Drug Interactions